UPB Stock Overview
A clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Upstream Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.96 |
| 52 Week High | US$29.46 |
| 52 Week Low | US$17.09 |
| Beta | 0 |
| 11 Month Change | -24.34% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -13.82% |
Recent News & Updates
Recent updates
Shareholder Returns
| UPB | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -16.6% | 4.0% | 2.0% |
| 1Y | n/a | 18.0% | 32.4% |
Return vs Industry: Insufficient data to determine how UPB performed against the US Biotechs industry.
Return vs Market: Insufficient data to determine how UPB performed against the US Market.
Price Volatility
| UPB volatility | |
|---|---|
| UPB Average Weekly Movement | 11.4% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.9% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: UPB's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine UPB's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 38 | E. Sutherland | upstreambio.com |
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Upstream Bio, Inc. Fundamentals Summary
| UPB fundamental statistics | |
|---|---|
| Market cap | US$1.00b |
| Earnings (TTM) | -US$69.59m |
| Revenue (TTM) | US$2.21m |
460.4x
P/S Ratio-14.6x
P/E RatioIs UPB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UPB income statement (TTM) | |
|---|---|
| Revenue | US$2.21m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.21m |
| Other Expenses | US$71.80m |
| Earnings | -US$69.59m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,153.10% |
| Debt/Equity Ratio | 0% |
How did UPB perform over the long term?
See historical performance and comparison